

COVID-19 PUTATIVE MITIGATION PATHWAYS: A CALL FOR CLINICAL TRIAL
tripartite combination of potential pandemic mitigation agents

**MITIGATION
STAGES**

PROFILAXIS

DISEASE SEVERITY MITIGATION

**MITIGATION
AGENTS**

VITAMIN D & QUERCETIN

VITAMIN D; QUERCETIN & ESTRADIOL

**MITIGATION
SUBJECTS**

**ALL ADULTS, PARTICULARLY, VOLNURABLE
INDIVIDUALS: OLDER ADULTS (> 65 YRS) & ELDERLY**

**INFECTED INDIVIDUALS; CONTACTS;
INDIVIDUALS IN QUARANTINE**

**MECHANISTIC
ENDPOINTS**

**DECREASED EXPRESSION OF HUMAN GENES
ENCODING ACE2 & FURIN PROTEINS**

**ALTERED EXPRESSION OF HUMAN GENES
ENCODING PROTEIN TARGETS OF SARS-CoV-2**

**CLINICAL
ENDPOINTS**

**DECREASED LIKELIHOOD OF INFECTION
DURING TRANSITION TO SOCIAL MOBILITY**

**DECREASED LIKELIHOOD OF DISEASE
PROGRESSION TO SEVERE OR LETHAL STAGE**